8-K: Teknova Announces Preliminary Q2 2024 Results and Reaffirms Full-Year Guidance

Teknova reports preliminary Q2 2024 revenue of $9.4 to $9.6 million and reaffirms its full-year revenue guidance of $35-38 million.

Summary

• Teknova has released preliminary unaudited financial results for the second quarter of 2024, ending June 30th.
• The company's total revenue for Q2 is expected to be between $9.4 and $9.6 million.
• This represents a 17% to 18% decrease compared to the second quarter of 2023.
• However, when adjusted for an unusually large Clinical Solutions order in Q2 2023, revenue increased by 7% to 9%.
• Teknova has reaffirmed its full-year 2024 revenue guidance of $35 to $38 million.
• The company anticipates a free cash outflow of less than $18 million for 2024, with $3.0 to $3.4 million used in Q2 2024.
• Teknova has reduced its headcount by more than 40% since its peak in Q2 2022, with 169 associates at the end of Q2 2024.
• The number of Clinical Solutions customers has increased from 34 in fiscal 2023 to 43.
• The number of Lab Essentials customers has increased from 2,829 to 2,913 since fiscal 2023.
• The company expects to report its complete financial results for Q2 2024 on August 13th, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reaffirmed revenue guidance and adjusted revenue growth, but tempered by the reported revenue decline and the preliminary nature of the results. The company's cost-cutting measures and increasing customer base are also positive indicators.

Positives

• Teknova has reaffirmed its full-year revenue guidance, indicating confidence in their performance.
• Adjusted revenue shows growth compared to the previous year, suggesting underlying business strength.
• The company is effectively managing costs, as evidenced by the significant reduction in headcount.
• The customer base is diversifying, with no single customer accounting for more than $1 million in revenue year-to-date.
• The number of customers in both Clinical Solutions and Lab Essentials has increased, indicating growing market adoption.
• On-time delivery metrics are at an all-time high, reflecting improved manufacturing efficiency.

Negatives

• Reported Q2 2024 revenue is down 17% to 18% compared to Q2 2023, before adjustments.
• The company expects lower overall revenue in the Clinical Solutions category for fiscal 2024 compared to fiscal 2023.
• The preliminary financial results are unaudited and may differ materially from the final results.

Risks

• The preliminary financial results are subject to change and may differ materially from the final results.
• The company's performance is subject to market conditions and the availability of funding in the biotech and cell and gene therapy sectors.
• There are risks related to demand for Teknova's products, including potential delays or pauses in customer orders.
• The company faces risks related to its supply chain, sourcing, manufacturing, and warehousing.
• Global economic and marketplace uncertainties, including conflicts in Ukraine and the Middle East, could impact the company.
• Reliance on a limited number of customers for a high percentage of revenue poses a risk.
• Potential acquisitions and integration of other companies could present challenges.

Future Outlook

Teknova is confident in its ability to deliver through the end of the year and beyond, particularly with improving market conditions and recent FDA approvals of novel gene therapies. The company expects continued growth in both Clinical Solutions and Lab Essentials.

Management Comments

• Stephen Gunstream, President and Chief Executive Officer, stated he is excited to share the company's sustained progress in executing against its strategy.
• He also expressed increasing confidence that the company will continue to deliver through the end of the year and beyond.

Industry Context

The announcement comes at a time when the biotech and cell and gene therapy sectors are showing signs of recovery, with recent FDA approvals and increased funding. This suggests a positive outlook for companies like Teknova that supply critical reagents to these industries.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without more specific information on Teknova's competitors.
• However, the company's focus on cell and gene therapy reagents aligns with a growing trend in the life sciences industry.
• The reported revenue decline compared to the previous year's quarter, while partially explained by a one-off order, suggests that Teknova is not immune to the broader market headwinds.
• The company's cost-cutting measures, including a significant reduction in headcount, are in line with actions taken by other companies in the sector to improve profitability.

Stakeholder Impact

• Shareholders will be interested in the company's revenue performance and cost management efforts.
• Employees have been impacted by the headcount reduction.
• Customers will be interested in the company's on-time delivery performance and product offerings.
• Suppliers will be interested in the company's financial stability and future growth prospects.

Next Steps

• Teknova will report its complete financial results for the second quarter of 2024 on August 13th, 2024.
• The company will continue to execute its strategy and manage operating expenses.

Key Dates

Keywords

reagents, biotech, cell and gene therapy, clinical solutions, lab essentials, revenue, financial results, free cash flow, manufacturing, customer base